The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory

Vaccines based on mRNA-containing lipid nanoparticles (LNPs) are a promising new platform used by two leading vaccines against COVID-19. Clinical trials and ongoing vaccinations present with varying degrees of protection levels and side effects. However, the drivers of the reported side effects rema...

Full description

Bibliographic Details

Published in:	iScience Vol. 24; no. 12; p. 103479
Main Authors:	Ndeupen, Sonia, Qin, Zhen, Jacobsen, Sonya, Bouteau, Aurélie, Estanbouli, Henri, Igyártó, Botond Z.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 17.12.2021 Elsevier
Subjects:	Biological sciences Biotechnology Immunology Biotechnology Biological sciences Immunology
ISSN:	2589-0042, 2589-0042
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!